Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 82, Issue 7, Pages 637-639Publisher
WILEY
DOI: 10.1002/ajh.20883
Keywords
bortezomib; multiple myeloma; proteasome; relapse; refractory
Categories
Ask authors/readers for more resources
Community practice experience allows a nonselective care of patient using information derived from a more controlled clinical trial environment. We present our community experience with multiple myeloma patients with advanced age, long disease duration since diagnosis, advanced stage, multiple prior therapies including stem cell transplantation, co-morbidities, and other poor prognostic features, such as low albumin, high B-2 microglobulin, renal failure, and the presence of poor risk chromosomal abnormalities. Our response rates are comparable to those from clinical trials. Bortezomib is well tolerated in this population of multiple myeloma patients with the exception of infection adverse events that are generally mild grade 1-2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available